ALK Biomarkers News and reporting on ALK biomarkers. Jan 28, 2022 Pfizer's Lorviqua Approved in EU for First-Line Treatment of ALK-Positive Advanced Lung Cancer Jan 18, 2022 Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology Premium Nov 15, 2021 Drugmakers Trying Out Decentralized Clinical Trials in Precision Oncology Though Risks Remain Premium May 17, 2021 Oncologists, Patients Still Face Unpredictable Payor Coverage for Broad Tissue NGS Panels Premium May 14, 2021 LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign Premium May 11, 2021 Nuvalent Raises $135M in Series B Funding Apr 12, 2021 Turning Point Therapeutics Initiates Phase I/II Trial of TPX-0131 in Lung Cancer Mar 4, 2021 FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx Jan 27, 2021 Nuvalent Launches With $50 Million in Series A Funding Jan 20, 2021 Inivata Begins Testing Lung Cancer Patients in ALKALINE Trial Jan 15, 2021 FDA Approves Pfizer's Xalkori for Pediatric ALK-Positive Lymphoma Dec 14, 2020 Daiichi Sankyo, AstraZeneca Begin Phase II Datopotamab Deruxtecan Trial in NSCLC Dec 10, 2020 UK's NICE Recommends Takeda's Alunbrig for ALK Inhibitor-Naïve Advanced NSCLC Nov 17, 2020 Research Groups Fund Phase III Trials of Pfizer's Lorbrena in Pediatric Neuroblastoma Sep 23, 2020 FDA Accepts Pfizer's sNDA for Xalkori in Rare ALK-Positive Pediatric Leukemia Indication Sep 20, 2020 Pfizer's Lorbrena Yields Impressive Responses in ALK-Positive NSCLC With Brain Metastases Premium Sep 14, 2020 COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials Aug 18, 2020 NCI SEER Registry Data Analysis Suggests Precision Medicine's Role in Fewer NSCLC Deaths Premium Aug 10, 2020 Xcovery's Ensartinib Extends PFS in First-Line Advanced ALK-Positive NSCLC Aug 5, 2020 Pfizer to Seek Approval for Lorbrena as First-Line Treatment for ALK-Positive Metastatic Lung Cancer Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
